BHC
Undervalued by 77.8% based on the discounted cash flow analysis.
Market cap | $2.59 Billion |
---|---|
Enterprise Value | $23.93 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-1.24 |
Beta | 1.1 |
Outstanding Shares | 366,796,721 |
Avg 30 Day Volume | 3,261,849 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -5.7 |
---|---|
PEG | 8.36 |
Price to Sales | 0.28 |
Price to Book Ratio | -1.69 |
Enterprise Value to Revenue | 2.67 |
Enterprise Value to EBIT | 14.31 |
Enterprise Value to Net Income | -53 |
Total Debt to Enterprise | 0.92 |
Debt to Equity | -19.8 |
No data
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...